ActiQs
Mer att utforska

Verktyg för dig

Combinations My watchlist

För professionella

Ämnesregister Source registry API & data
ActiQs / Research
PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för cabotegravir. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

33 hits
Bibliografisk träff 2021-07-01

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.

Cutrell AG, Schapiro JM, Perno CF, Kuritzkes DR, Quercia R, Patel P, Polli JW, Dorey D, Wang Y, Wu S, Van Eygen V, Crauwels H, Ford SL, Baker M, Talarico CL, Clair MS, Jeffrey J, White CT, Vanveggel S, Vandermeulen K, Margolis DA, Aboud M, Spreen WR, van Lunzen J.

AIDS · research support, non-u.s. gov't; research-article; journal article · DOI 10.1097/qad.0000000000002883
Bibliografisk träff 2021-05-01

Cabotegravir Sodium.

Författaruppgift saknas

Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxab090
Bibliografisk träff 2021-05-01

Cabotegravir and Rilpivirine.

Författaruppgift saknas

Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxab088
Bibliografisk träff 2021-04-01

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.

Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, García JG, Morell EB, Tan DHS, D'Amico R, Dorey D, Griffith S, Thiagarajah S, St Clair M, Van Solingen-Ristea R, Crauwels H, Ford SL, Patel P, Chounta V, Vanveggel S, Cutrell A, Van Eygen V, Vandermeulen K, Margolis DA, Smith KY, Spreen WR.

Lancet HIV · clinical trial, phase iii; equivalence trial; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s2352-3018(20)30340-4
Bibliografisk träff 2020-12-19

Design and Testing of a Cabotegravir Implant for HIV Prevention.

Karunakaran D, Simpson SM, Su JT, Bryndza-Tfaily E, Hope TJ, Veazey R, Dobek G, Qiu J, Watrous D, Sung S, Chacon JE, Kiser PF.

J Control Release · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jconrel.2020.12.024
Bibliografisk träff 2020-12-09

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, García Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W.

Lancet · clinical trial, phase iii; equivalence trial; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/s0140-6736(20)32666-0
Bibliografisk träff 2020-12-01

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.

Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masiá M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA.

J Acquir Immune Defic Syndr · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1097/qai.0000000000002466
Bibliografisk träff 2020-04-27

A year-long extended release nanoformulated cabotegravir prodrug.

Kulkarni TA, Bade AN, Sillman B, Shetty BLD, Wojtkiewicz MS, Gautam N, Hilaire JR, Sravanam S, Szlachetka A, Lamberty BG, Morsey BM, Fox HS, Alnouti Y, McMillan JM, Mosley RL, Meza J, Domanico PL, Yue TY, Moore G, Edagwa BJ, Gendelman HE.

Nat Mater · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/s41563-020-0674-z